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CASE REPORT Open Access
Gamma-delta (γδ) T-cell lymphoma –
another case unclassifiable by World Health
Organization classification: a case report
Hemant Sindhu1, Ruqin Chen1, Hui Chen1, Jonathan Wong2, Rashid Chaudhry2, Yin Xu3 and Jen C. Wang1*
Abstract
Background: We present a case of gamma-delta T-cell lymphoma that does not fit the current World Health
Organization classifications.
Case presentation: A 74-year-old Caribbean-American woman presented with lymphocytosis, pruritus, and non-
drenching night sweats. Bone marrow and peripheral blood analyses both confirmed the diagnosis of gamma-delta
T-cell lymphoma. An axillary lymph node biopsy was negative for lymphoma. Clinically absent hepatosplenomegaly
and skin lesions with biopsy-proven gamma-delta T-cell lymphoma suggest that she is unclassifiable within the
current classification system.
Conclusions: We believe this is a case of not otherwise specified gamma-delta T-cell lymphoma. Accumulation of
these rare not otherwise specified cases will be important for future classification which further defines the biology of
this disease.
Keywords: Gamma-delta T-cell lymphoma (Tγδ cell lymphoma), T-cell lymphoma NOS, Case report, Hepatosplenic Tγδ,
Cutaneous Tγδ
Background
T lymphocytes recognize antigens through T cell recep-
tors (TCRs). TCRs are polypeptide heterodimers which
are commonly made up of α and β chains and rarely of γ
and δ chains. Gamma-delta T cells (Tγδ) thus represent
less than 5% of all peripherally circulating lymphocytes
and of all T cells in mucosa, these cells can account for up
to 50%. Tγδ have a selective tropism for the red pulp of
the spleen, mucosal tissues, and lymphoid tissues, as well
as gastrointestinal epithelial tissues and skin [1]. The ma-
jority of the lymphoid tissues, however, are distributed by
the alpha-beta T cell. Therefore, the alpha-beta receptor T
cells are expressed in most T-cell lymphomas (TCLs), and
gamma-delta TCR is expressed by less than 5% of TCL.
Tγδ cell lymphoma represents a rare and aggressive set of
neoplasms which portend a very poor prognosis [2]. In
2008, the World Health Organization (WHO) redefined
its classification of Tγδ cell lymphoma into two groups:
hepatosplenic Tγδ cell lymphoma (HSγδTL) and primary
cutaneous TCL (PCTCL) [3]. Tripodo et al. asserted that
the 2008 WHO classification accounts for the cellular,
phenotypic, and molecular properties of hematopoietic
and lymphoid tissues in this updated classification [4]. In
2016, the WHO classification of T Tγδ cell lymphoma did
not add much [5]. Although the WHO classification is
helpful in defining the subtypes of lymphomas, the rare en-
tities comprising peripheral TCLs (PTCLs) remain less well
understood given their low incidence as well as the nebu-
lous nature of the T cell system [6]. HSγδTL is most com-
monly seen in young immunocompromised men aged 20
to 25 years. Variations in age of presentation are possible
with Crohn’s disease where younger patients including
children are afflicted. Recipients of solid-organ transplants
are more likely to present at a later age. PCTCL does not
show a gender predisposition, but is described in older pa-
tients with a median age of 60 years [7]. PCTCL occurs in
less than 1% of cases of primary cutaneous Tγδ cell lymph-
oma; those with cutaneous involvement demonstrate a
poor prognosis. Here we describe a case of a 74-year-old
woman with biopsy-proven Tγδ cell lymphoma that fits
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neither of the two classifications of Tγδ cell lymphoma be-
cause she does not have hepatosplenomegaly and neither
does she exhibit the typical cutaneous manifestations. This
report adds to the database of these atypical cases of Tγδ
cell lymphoma not classified by the current WHO criteria.
Case presentation
A 74-year-old Caribbean-American woman was referred
by her primary care physician for evaluation of lymphocy-
tosis. She complained of generalized itching and non-
drenching night sweats, and denied any unexpected
weight loss. Her past medical history is significant for
breast cancer treated with mastectomy in 2001. At the
time of presentation, she was not taking any medication
and had no history of tobacco smoking or recreational
substance use. She is a homemaker and immigrant whose
only positive family history is breast cancer in her mother
diagnosed at age 80 years. Her physical examination was
grossly normal revealing no cutaneous lesions and no
hepatosplenomegaly, but there were two palpable axillary
lymph nodes measuring 2 to 3 cm.
Her white cell count was 11.3×109 cells/L, with a prom-
inent absolute lymphocyte count (7.5×109/L) and in-
creased atypical mature lymphocyte (Fig. 1). She also had
elevated levels of creatinine (1.3 mg/dL), immunoglobulin
G (IgG) (2037 mg/dL), and lactate dehydrogenase (397
IU/L). Her transaminases and tests of liver function were
unremarkable. A computed tomography (CT) scan re-
vealed axillary and abdominal portacaval lymphadenop-
athy. A positron emission tomography (PET)-CT scan
showed fluorodeoxyglucose (FDG) avidity in her left axil-
lary and inferior portacaval nodes as well as the bone mar-
row. Flow cytometry of her peripheral blood revealed 37%
aberrant Tγδ, which were positive for CD2, CD3(dim),
CD5, CD7, TCR gamma-delta, and negative for CD1a,
CD4, CD8, CD10, CD16, CD25, CD56, CD57, terminal
deoxynucleotidyl transferase (TdT), and TCR alpha-beta
(Fig. 2). Molecular analysis also demonstrated TCRs with
gamma-delta rearrangements, which supported a mature
T (γδ) clonal proliferative disease. A subsequently
performed bone marrow biopsy revealed both para-
trabecular and interstitial aggregates of small-sized to
medium-sized lymphocytes which stained predominantly
positive for T cells (Fig. 3a–c). Immunohistochemistry
showed that the CD3/CD5-positive T cells were negative
for both CD4 and CD8 as well as TIA-1 and Granzyme
B. Flow cytometry of the bone marrow aspirate detected
26% TCR Tγδ with the same immunophenotype as
seen in the blood. Together, the bone marrow findings
were consistent with marrow involvement by a mature
gamma-delta T cell neoplasm. The lymph node biopsy
showed preserved nodal architecture with many
lymphoid follicles. Since the lymph node architecture
was preserved, it was probable that the lymph nodes
were not involved in the pathology. This diagnosis
was made after consultation with Dr Elaine Jaffe at
the National Institutes of Health (NIH). Cytogenetics
was normal in the bone marrow as well as in the lymph
node biopsies. Fluorescence in situ hybridization (FISH)
utilized probes specific for T cell neoplasm including
1p/1q, 5/5q, 7/7q, centromere 8, and 14q11 did not
detect any aberrations in all 200 nuclei examined. Our
patient was started on cyclophosphamide, vincristine,
doxorubicin, and prednisone (CHOP). She experienced
grade 4 nausea and vomiting and was hospitalized
twice with febrile neutropenia. Through the course of
treatment, step-wise dose reductions were made due
to intolerability. An interval PET-CT in December 2015
revealed a favorable radiographic and scintigraphic
response to treatment. Specifically, there was resolution
of previously identified lymphadenopathy below her
diaphragm. A mildly FDG-avid slightly enlarged level I
lymph node was present in the right axilla. There was
FDG accumulation throughout the bone marrow sug-
gestive of treatment-related hyperplasia, but no definite
evidence of focal areas of more pronounced FDG accu-
mulation was present within her osseous structures,
which showed resolution. She received a total of eight
cycles of CHOP, the final cycle being dose-reduced by
70%. In March 2016, PET-CT revealed recurrence of
hypermetabolic lymphadenopathy in her right axillary,
supraclavicular, and left hilar regions. Her symptoms of
itching and night sweats also returned. She refused any
further intervention. She subsequently developed emboli
in her feet bilaterally without an evident source. There
were no atrial or valvular vegetations visible on transtho-
racic echocardiography. She underwent bilateral below-
the-knee amputations and she eventually succumbed to
pneumonia postoperatively in 2016; she survived ap-
proximately 16 months post-diagnosis.
Fig. 1 Atypical lymphocytosis. The blood smear shows increased
small-sized to medium-sized lymphocytes with mature chromatin
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Discussion
It is the taxonomy and classification of diseases that
form the linguistics of medicine. Hence we rely on our
guidelines and cataloging to aid us in diagnosis and
guide us with treating our patients. Just as our know-
ledge evolves, so must our system of categorizing. In this
2008 WHO update, as published in the fourth edition of
the Classification of Tumours of Haematopoietic and
Lymphoid Tissues, which built on the third edition pub-
lished in 2001, precursor lesions of lymphoid neoplasms
earned more notoriety through sub-classification [3]. It
is in fact the Revised European-American Lymphoma
(REAL) classification which provides the foundation for
the WHO system [8]. Although the WHO classification
is helpful in defining the subtypes of lymphomas, the
rare entities comprising PTCLs remain less well under-
stood given their low incidence as well as the nebulous
nature of the T cell system [9]. Further down the taxo-
nomic framework of PTCLs, Tγδ cell lymphomas were
disambiguated into two main entities: hepatosplenic
TCL (HSTL) and primary cutaneous gamma-delta TCL
(PCγδ-TCL).
Tγδ cell lymphomas are neoplasms which arise from
a very small subset of T lymphocytes expressing
gamma-delta TCRs. Similar to their B cell counterparts,
T lymphocytes use these receptors for cell or antigen
recognition; the receptor itself a heterodimer which
comprises either the more common alpha-beta com-
bination or, less commonly, the gamma-delta amal-
gamation [10]. The gamma-delta cells human γδ T
lymphocytes originate from CD4-CD8- double negative
progenitor cells [11]. The gamma-delta T cell popula-
tion is further divided based on differences in the vari-
able receptor region: Vdelta1 and Vdelta2 [4]. These
two subpopulations are not only distinct in their
phenotypic variance, but also by their distribution as
Vdelta1 cells are most commonly found in the gas-
trointestinal tract whereas Vdelta2 cells have a pre-
ponderance for the skin and lymphoid tissue [12]. Of
the two subtypes of gamma-delta TCLs, HSTL was the
first to be described in the literature; HSTL is classic-
ally described as having the gamma-delta phenotype
(preferentially derived from Vdelta1 type) with only
rarely described cases harboring the alpha-beta subtype
[13]. Clinically, HSTL is a disease primarily described
in young men, especially in those who have been ex-
posed to chronic immunosuppressants [12]. In addition
to young adults having the risk factor of chronic in-
flammation such as Crohn’s disease, it has been de-
scribed in the setting of those individuals with chronic
hepatitis B infection [14]. The most common physical
finding is splenomegaly, and hepatomegaly is noted in
nearly 90% of cases whereas there is a complete lack of
lymphadenopathy. Symptoms that often bring individ-
uals to the clinical setting are B symptoms, early satiety,
abdominal pain, and weakness [15]. Laboratory data
usually reflect transaminitis, and elevations in alkaline
phosphatase and lactate dehydrogenase. Cytopenias are
commonly seen, thrombocytopenia being the most
common (85% of cases) followed by anemia (75% of
cases) [16]. The mucocutaneous gamma-delta TCLs can
be divided into those localized to the skin and those in-
volving the nasal cavity, the bowel, the respiratory tract,
and the thyroid. Both these entities, however, prefe-
rentially derive from the Vdelta2 cells subset and tend
to have an activated cytotoxic profile (TIA1+, Gran-
zyme B+, Perforin+) [12].
Based on laboratory data including findings on bone
marrow biopsy and peripheral blood findings, our pa-
tient has a definite diagnosis of a mature gamma-delta
TCL. However, her clinical findings are not consistent
with either of the two WHO classifications given that
she has no hepatosplenomegaly and lacks the typical
cutaneous manifestations. Moreover, our 74-year-old pa-
tient fits neither age range of the two subtypes of γδ-
TCL. The hepatosplenic variant has been better studied
and as per previous reports, the median age of hepatos-
plenic γδ-TCL is less than 40 years, with the oldest re-
ported age of 64 years. It is further reported that
approximately 10 to 20% of patients have a prior history
of immunocompromise, which is not present in our pa-
tient. Our patient’s lack of the expression of Granzyme B
+ and Perforin staining coupled with the absence of skin
involvement makes the diagnosis of PCγδ-TCL unlikely.
Fig. 2 Identification of aberrant gamma-delta T cells by flow cytometry. a A predominant population of T cells with dim CD3 expression. b The
CD3 dim-positive T cells are dual negative for CD4 and CD8. c The CD3 dim-positive T cells are positive for T cell receptor gamma-delta
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The lack of overt lymph node involvement in our patient
is also described in cases of HSTL and PCγδ-TCL [12].
For these patients with Tγδ cell lymphoma, the median
survival reported is 1 to 2 years and there is no standard
treatment which has proven to be effective. Those pa-
tients treated with chemotherapy tended toward a longer
survival. There is a single report of a patient treated with
allogeneic stem cell transplant which revealed a survival
longer than 7 years. Data suggest that women have lon-
ger overall survival compared to men (25 months versus
8 months) [17, 18].
Conclusions
Our patient is among the first of such cases described in
the literature whose age, presentation, and laboratory
findings do not fit neatly into either of the two WHO
classifications of γδ-TCL. Since many of these rare cases
of Tγδ cell lymphoma remain unclassifiable, a literary
accumulation of these reports will be important for fu-
ture classification.
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Fig. 3 Bone marrow involvement by T-cell lymphoma. a Paratrabecular
and interstitial lymphoid aggregates. b CD3 immunostaining highlights
T cells in the aggregates. c Small-sized to medium-sized atypical
lymphocytes with mature chromatin
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